


# THE INNODIA PATIENT GROUP EXTRA NEWS

PAC - Patient Advisory Committee - was created to put the patients and their family at the center of the project, giving them a voice in the decisions that affect how they receive care. 8 patients and 2 family members meet on a monthly base to discuss ideas and suggestions and to give their input in the progression of the study.

A humanized mouse Strain that develops spontaneously immune-mediated diabetes.

## Bridging the gap between mouse and men



Our preclinical mouse models of type 1 diabetes have fallen short of translating into human. Due to the existing gap between mouse and men, therapies that have proven to be successful in mice often show poor clinical significance when tested in humans. By replacing diabetes-related mouse genes with their human counterpart, the authors of this publication attempt to close the gap between mouse and men. In these so called ‘humanized mice’, therapies can be tested that could directly apply to the human situation. Altogether, these new models could overcome the poor translation to humans and provide a larger set of preclinical tools to study human type diabetes.

*Original publication: A Humanized Mouse Strain That Develops Spontaneously Immune-Mediated Diabetes Luce S, Guinoiseau S, Gadault A, Letourneur F, Nitschke P, Bras M, Vidaud M, Charneau P, Larger E, Colli ML, Eizirik DL, Lemonnier F, Boitard C. Front Immunol. 2021 Oct 14;12:748679. doi: 10.3389/fimmu.2021.748679. eCollection 2021. PMID: 34721418'*

INNODIA is a unique and interdisciplinary network of 40 partners, including preeminent academic institutions from Europe, industrial partners, charitable foundations and small sized enterprises, bringing together their knowledge and experience to achieve one common goal: "To fight type 1 diabetes". Launched in January 2016, this European-based public private partnership (PPP) receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (Grant Agreement Number: 115797) and is supported by the European Union's Horizon 2020 Research and Innovation program, European Federation of Pharmaceutical Industries and Associations (EFPIA), The Leona M. and Harry B. Helmsley Charitable Trust and JDRF.

INNODIA aims to improve the understanding of type 1 diabetes and pave the way for the development of novel therapies to prevent and cure it.